R&D tax incentive, page-20

Just after the final results came through I knew some people who consulted in the Biotech field and ITHO they were;
1. surprised about the heavy weighting towards the Russian cohort.
2. surprised by ACL's attitude that all the research/study of HA that the trial was based on was worthy of the study only to suddenly be "worthless."
3. they believed there maybe oppurtunities for the HA technology albeit differently to those pursued by ACL.
4. FAK inhibitors (anyone know what happened to that) also may hold some future potential.
From memory asx longtail may also have expressed similar views for some of these techs.
GLTA .